Business Model & Revenue
Co-Diagnostics, Inc. (NASDAQ: CODX) is a Salt Lake City, Utah-based molecular diagnostics company. Founded in 2013, the company developed proprietary PCR (polymerase chain reaction) testing technology used primarily for COVID-19 testing during the pandemic.
Revenue model (historical): Sale of PCR test kits, reagents, and diagnostic instruments. During COVID (FY2021), revenue peaked at $298M. The company manufactured and sold COVID test kits globally, with significant revenue from international markets including India.
Revenue model (current): Minimal. Q1 2026 revenue was $146K. The company is attempting to pivot its PCR technology platform (Co-Dx PCR) to new diagnostic applications: tuberculosis (TB clinical studies in India), respiratory pathogen panels, women's health, and multiplex testing.
Joint ventures:
- CoMira (Saudi Arabia): PCR manufacturing JV in Saudi Arabia aligned with Vision 2030 healthcare localization. CODX provides PCR technology; Saudi partners provide manufacturing facility, capital, and market access. Reported $13B addressable market across diagnostics applications.
- CoSara (India): JV for PCR Pro instrument manufacturing and diagnostic test distribution. Expanded commercial scope announced in South Asia.
The company has no commercial products generating meaningful revenue post-COVID. All revenue is from legacy testing contracts and early-stage product sales. The business model is entirely dependent on successfully commercializing the Co-Dx PCR platform and monetizing international JVs.
Financial Highlights
Q1 2026 Results
| Metric | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $0.15M | $0.05M | +192% |
| Operating Expenses | $9.2M | $8.6M | +7% |
| Net Loss | ($9.1)M | ($7.5)M | +21% worse |
FY2025 Annual
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $0.62M | $3.93M | $26.81M | $134.2M | $297.9M |
| Revenue Growth | -84.1% | -85.3% | -80.0% | -55.0% | +31.3% |
| Operating Income | ($40.1)M | ($42.7)M | ($27.0)M | $46.1M | $46.1M |
| Net Income | ($46.9)M | ($37.6)M | ($35.3)M | $36.7M | $36.7M |
| R&D | $20.2M | $22.96M | $17.44M | $14.96M | — |
| FCF | (~$50M) | (~$40M) | (~$26M) | — | — |
Key Metrics
| Metric | Value |
|---|---|
| Market Cap (post-surge) | ~$52M |
| Shares Outstanding | 21M |
| Share Dilution (YoY) | +58% |
| TTM Revenue | $720K |
| Price/Sales (TTM) | 72x |
| Quarterly Burn Rate | ~$9.1M |
| Cash (estimated) | ~$15-20M |
The COVID Collapse
| Year | Revenue | Context |
|---|---|---|
| FY2021 | $297.9M | COVID testing peak |
| FY2022 | $134.2M | Declining COVID testing |
| FY2023 | $26.8M | COVID testing collapsed |
| FY2024 | $3.93M | Near-zero |
| FY2025 | $0.62M | Effectively zero |
| Decline | -99.8% | Complete revenue destruction |
Revenue went from $298M to $620K. The company lost $196.8M cumulatively over 4 years while trying to build a post-COVID business. The R&D spending of $20.2M/year has produced $146K in quarterly revenue.
Valuation Absurdity
| Metric | CODX | Context |
|---|---|---|
| Market Cap | $52M | For $720K TTM revenue |
| Price/Sales | 72x | SaaS averages 10-15x |
| Quarterly Revenue | $146K | Less than a single PCR instrument sale |
| Quarterly Loss | ($9.1)M | 62,000% of revenue |
| Years of Cash Left | ~2 quarters | Without financing |
CODX is priced like a growth company but operating like a company in liquidation.
Competitive Landscape
The PCR diagnostics market is mature and dominated by large incumbents:
- Thermo Fisher Scientific (TMO): $40B+ market cap. Dominates PCR reagents, instruments, and consumables globally.
- Bio-Rad (BIO): $3B+ market cap. Major PCR diagnostics player with established distribution.
- Abbott (ABT), Roche (RHHBY), Qiagen (QGEN): Established molecular diagnostics platforms with global reach.
- Cepheid (owned by Danaher DHR): Point-of-care PCR testing leader. Dominant in rapid diagnostics.
- Hologic (HOLX), Becton Dickinson (BDX): Large diagnostic companies with PCR capabilities.
CODX's challenge: The PCR diagnostics market is commoditized. Primers, probes, and reagents are available from dozens of suppliers at competitive prices. Co-Diagnostics' proprietary Co-Dx PCR technology needs to demonstrate clear advantages in speed, accuracy, cost, or ease-of-use to compete against incumbents with established sales channels and brand recognition.
The Saudi JV angle: CoMira could provide a protected market in Saudi Arabia (government preference for domestic manufacturing under Vision 2030). But it doesn't solve the global competitiveness problem. If the Co-Dx PCR platform can't compete internationally, the Saudi JV's addressable market shrinks to domestic Saudi demand only.
The TB angle: TB diagnostics in India could be a differentiated niche. India has the world's highest TB burden. If CODX's TB test offers advantages over existing GeneXpert (Cepheid) or smear microscopy, it could capture meaningful market share. But clinical validation, regulatory approval, and commercial scaling in India take years and require significant capital.
Catalysts
-
CoMira Saudi JV milestones: Facility construction completion, first manufacturing orders, commercial revenue generation. Timeline: 2027-2028 for meaningful revenue.
-
Co-Dx PCR FDA submission: If management provides a firm FDA submission date, it removes timeline uncertainty. Management "updated" the timeline on Q1 call but no specific date given.
-
TB clinical studies in India: Launch timeline described as "imminent." If initiated, provides a second clinical validation pathway.
-
CoSara (India JV): Expanded commercial scope in South Asia with $13B addressable market. Revenue from this JV has been minimal to date.
-
Partnership/licensing deals: If CODX licenses its PCR technology to a larger diagnostic company, it could generate upfront payments and royalties.
Reality: None of these catalysts address the $146K quarterly revenue. Every catalyst is forward-looking and uncertain. The company needs a funded partnership or capital injection to survive long enough to realize any of them.
Key Risks
- Revenue collapsed 99.8% from $298M (FY2021) to $720K (TTM). No sustainable post-COVID revenue stream.
- $146K Q1 revenue vs $9.1M quarterly loss. The company burns 62,000% more than it earns.
- $32.3M TTM operating expenses on $720K revenue. The cost structure is absurd relative to revenue.
- 58% share dilution YoY (13.3M → 21M shares). Further dilution almost certain.
- CoMira Saudi JV is years from generating revenue. 'Execution phase' = construction + hiring + regulatory approvals.
- Co-Dx PCR platform needs FDA submission and clinical validation. No firm timeline provided.
- $52M market cap for $720K TTM revenue = 72x P/S. Even generous Saudi JV revenue assumptions don't justify this.
- No analyst coverage. Zero institutional following. Limited liquidity.
- Cash burn of $9.1M/quarter with minimal revenue. Cash reserves will be depleted without financing.
- COVID testing market is dead. The revenue recovery story is entirely dependent on new products and partnerships that don't yet exist.
Our Thesis
Co-Diagnostics is a COVID testing company that failed to build a sustainable post-COVID business. Revenue collapsed from $298M (FY2021) to $720K (TTM) — a 99.8% decline. The company burned through its COVID windfall on R&D ($20.2M in FY2025) and operating expenses ($32.3M TTM) without generating meaningful new revenue.
The Saudi JV (CoMira) is the bull case. Saudi Arabia's Vision 2030 initiative is investing heavily in domestic healthcare manufacturing. A PCR manufacturing facility with $13B addressable market and government backing is a real opportunity. If CoMira generates even $10-20M in annual revenue for CODX's share, it would transform the financial picture. The ESCMID presentation adds scientific credibility. The Co-Dx PCR platform could have applications beyond COVID (TB, respiratory panels, women's health).
But the numbers don't support the current valuation. $146K in Q1 revenue against $9.1M in losses means CODX is burning $30,000 for every $500 it earns. The company has 21M shares outstanding (58% dilution YoY). Cash reserves are limited — the company will likely need to raise capital, diluting shareholders further. The Saudi JV is years from meaningful revenue. The FDA submission timeline was "updated" on the Q1 call but no firm date was given.
At 72x TTM revenue, CODX is pricing in Saudi JV success that hasn't happened yet. If the JV works, the stock could re-rate. If it doesn't, the stock goes to $1 or below. The risk/reward is unattractive at the current price. Avoid.
Get reports like this delivered free
New small-cap research every week. No paywall, no fluff.